URGN · UroGen Pharma Ltd.
$46.37
-0.43 (-0.92%)
At close · Aug 21
Going-concern doubt
— cleared Aug 5, 2026
The latest filing states the doubt was alleviated.
“Based on our cash and cash equivalents and marketable securities as of June 30, 2026, together with management's cash flow projections, we believe we have sufficient cash and cash equivalents to fund our operations beyond one year from the issuance of our condensed consolidated financial statements appearing elsewhere in this Quarterly Report.”View the 10-Q filed Aug 5, 2026
Market Cap
$2.29B
Shares
48.88M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$46.80
Open$49.71
Day$46.20–49.71
52W close$16.42–50.29
Avg vol 30d941K
Short int4.6M · 9.4% float · 6.6d
Short vol45%
Last earningsAug 5, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 5
Up next
Next earnings call
Nov 4, 2026
Est · unconfirmed
· in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 5, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+73%
above
Price vs 50-day avg
+17%
above
RSI (14)
58
neutral
MACD trend
Positive
52-week position
90%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+10%
trailing
6-month return
+116%
trailing
YTD return
+100%
this year
Relative strength
+105%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $40 › 200d $27 — 50d above 200d
Institutional flow
Accumulating
+8% holders QoQ · +39 funds added
Insider flow
Distributing
Net -$142.6K over 90 days · 100% sells
Short interest
Falling
9.39% of float · ▼ -19.3% MoM · 6.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
189 holders — near 3-yr high, broad support
Squeeze score
70
elevated · 0–100
Fundamentals
Revenue growth
−86%
Y/Y
Gross margin
8630%
expanding
Free cash flow
$-162.7M
Balance sheet
$11.5M
net debt
Quant / Vol
risk profile
Volatility
67%
annualized · 1-yr
Max drawdown
−42%
past year
ATR
4.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 5, 2026
2026 net product revenue for JELMYTO
· full-year 2026
Initiated
$97M – $101M
Full-year 2026 operating expenses
· full-year 2026
Initiated
$260M – $270M
Non-cash share-based compensation expense
· full-year 2026
Initiated
$20M – $24M
Prior guidance
period ended
· from the 8-K filed Nov 6, 2025
Net product revenues for JELMYTO
· full-year 2025
$94M – $98M
Operating expenses
· full-year 2025
$215M – $225M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+73%
Bullish
Price vs 50-day avg
+17%
Bullish
RSI (14)
58
Neutral
MACD trend
Positive
Bullish
52-week position
90%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $40 › 200d $27 — 50d above 200d
Institutional flow
Accumulating
+8% holders QoQ · +39 funds added
Insider flow
Distributing
Net -$142.6K over 90 days · 100% sells
Short interest
Falling
9.39% of float · ▼ -19.3% MoM · 6.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
189 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $16
Now $47 · 90%
Range high $50
vs 200-day avg +73%
vs 50-day avg +17%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| activated sites of care | 1,444 | second quarter 2026 | — |
|
|
|||
| repeat ZUSDURI prescribers | 204 | second quarter 2026 | — |
|
|
|||
| repeat ZUSDURI prescribers percentage of total prescribers | 45% | second quarter 2026 | — |
| unique ZUSDURI prescribers | 452 | second quarter 2026 | — |
|
|
|||
| ZUSDURI net product sales | $50.43M | FY2026 Q2 | — |
|
|
|||
| JELMYTO underlying demand revenue growth | 7% | full year 2025 | — |
| UGN-103 three-month complete response rate | 77.8% | Phase 3 UTOPIA trial | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
URGN
this stock
UroGen Pharma Ltd.
|
$2.29B | +99.8% | -86.2% | — | 9.4% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +21.5% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
MRNA
Moderna, Inc.
|
$69.62B | +352.1% | +4.3% | — | 12.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| URGN | -2.7% | +10.1% | +115.7% | +22.4% | +99.8% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | -0.8% | +6.8% | +104.5% | +20.3% | +88.0% |
Key facts
CIK
1668243
CUSIP
M96088105
13F (30d)
183 filings
180 filers
Visit website
Investor relations